Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Cornu cervi pantotrichum pharmacopuncture solution significantly promoted hair growth in mice by enhancing hair follicular cell proliferation and up-regulating FGF-7 expression.

This study found that 54% of participants with androgenetic alopecia using Ricapil® showed clinical signs of hair follicle reactivation and initial hair regrowth over three months.

This study found that the new cocrystal formulation KET-PABA improved the antimycotic efficiency of ketoconazole and induced an anti-inflammatory response without causing skin sensitization in mice.

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

This study found that topical application of a cosmetic formulation containing capryloyl glycine 4% significantly reduced hair growth and thickness on the forearms of female participants after 120 days, compared to placebo.

This case report describes a patient who developed severe alopecia and a rash after increasing captopril dosage, which resolved upon discontinuing the medication.

This study suggests that APC collagen peptides may accelerate hair growth and promote overall hair health by enhancing cellular proliferation and activating specific signaling pathways in human and mouse models.

This article reviews DPCP's use as a topical immunotherapy for alopecia areata and discusses its suggested mechanism, but reports no clinical results.

This study found that topical application of partial proteasomal inhibitors accelerates hair growth by stabilizing β-catenin and disrupting the hair cycle's normal balance of activation and quiescence.

This study found that topical DPCP was more effective for hair regrowth in resistant alopecia areata compared to anthralin, with both treatments having similar safety profiles.

This study found that the oral Janus kinase inhibitor CP-690,550 has a direct effect on reducing pruritus in patients with psoriasis, independent of clinician-assessed improvements in psoriasis severity.

This case report suggests that frequent application of diphenylcyclopropenone 2% solution to the scalp for alopecia areata may lead to scalp angioedema.

This study found that procyanidin B-2 may promote hair growth by reducing expression and inhibiting translocation of PKC isozymes in murine hair epithelial cells.

Cyproterone Acetate effectively treats androgen-related conditions and is used in prostate cancer therapy and hormone therapy for transgender women.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

This study found that higher concentrations of topical diphenylcyclopropenone, especially when prepared with acetone, showed better stability over 6 months compared to lower concentrations.

This study found that monthly oral prednisolone pulses of 300 mg were effective and safe for treating widespread alopecia areata, with 58.3% of patients achieving cosmetically acceptable hair growth.

This study found that topical diphenylcyclopropenone is an effective treatment for extensive alopecia areata, with significant hair regrowth reported in most patients, though effectiveness varied with disease characteristics.

This study describes the diagnosis and successful management of Cronkhite-Canada syndrome in a 78-year-old man, highlighting improvement in symptoms and endoscopic findings after treatment with prednisone and supportive therapies.

This study found that bimatoprost stimulated hair growth in both human scalp follicle cultures and mouse pelage in vivo, suggesting it might offer a promising treatment for scalp alopecias.

In this study, combination therapy with DPCP and anthralin promoted hair regrowth in 40.62% of alopecia areata patients who were unresponsive to DPCP alone, with response improving over longer treatment durations.

This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.

This phase 2a trial evaluated Samcyprone for common wart treatment and found that while a sensitization reaction is necessary for therapeutic response, its level does not predict wart clearance.

Diphencyprone initially increases mouse hair growth, then slows it, possibly due to changes in specific protein levels.

Applying valproic acid on the scalp increased hair growth in men with hair loss.

Diphencyprone treatment protocols could be simplified as no harm occurred despite not fully following them.

This review discusses the mechanisms associated with protoporphyrin IX in living cells and reports no clinical results; the authors emphasize its potential in cancer diagnosis and the risks of toxicity.

This study found that adding PRP to DPCP treatment for severe alopecia areata did not enhance effectiveness compared to DPCP alone.

This study found that AHCC significantly reduced alopecia caused by Ara-C in neonatal rats and improved liver function affected by 6-MP and MTX in mice.